Market research
AYLA Ayala Pharmaceuticals Inc
NASDAQ USD Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 1.99
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Not available
- Industry
- Not available
- ISIN
- US05465V1089
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- 0.0%
- Beta
- 1.99
About
About Ayala Pharmaceuticals Inc
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AYLA discussion.
5 years, 4 months ago
Ayala Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 25.6% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.8.
Based on the above factors, Ayala Pharmaceuticals, Inc gets an overall score of 1/5.